Trial reportOphthalmology2011
SCORE Study report #11: incidences of neovascular events in eyes with retinal vein occlusion.
Trial report in Ophthalmology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00105027 (The Standard Care vs. COrticosteroid for REtinal Vein Occlusion), which is not on this map. Cited by 33 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study: Two Randomized Trials to Compare the Efficacy and Safety of Intravitreal Injection(s) of Triamcinolone Acetonide With Standard Care to Treat Macular Edema
Who cites it
33 citing papers in PubMed, 6 syntheses or guidelines pooled it, 75 citations in OpenAlex.
- Pooled it
- Comparison of the efficacy and safety of drug therapies for macular edema secondary to central retinal vein occlusion.BMJ open · 2018Pooled it
- Drug treatment of macular oedema secondary to central retinal vein occlusion: a network meta-analysis.BMJ open · 2014Pooled it
- Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion.The Cochrane database of systematic reviews · 2014Pooled it
- Treatments for macular oedema following central retinal vein occlusion: systematic review.BMJ open · 2014Pooled it
- Efficacy and safety of intravitreal therapy in macular edema due to branch and central retinal vein occlusion: a systematic review.PloS one · 2013Pooled it
- Retinal Characteristics in Eyes With Retinal Vein Occlusion Using Widefield Swept-Source Optical Coherence Tomography Angiography.Investigative ophthalmology & visual science · 2026Article
- Analyzing the changing trend of corneal biomechanical properties under different influencing factors in T2DM patients.Scientific reports · 2024Article
- Pattern and Prevalence of Retinal Vein Occlusion in Bhutan: A 3-Year National Survey at Vitreoretinal Clinics.Clinical ophthalmology (Auckland, N.Z.) · 2024Article
- Central retinal vein occlusion in young population: risk factors and outcomes.Frontiers in medicine · 2023Article
- The progress of assessment methods and treatments of neovascular glaucoma secondary to central retinal vein occlusion.Frontiers in medicine · 2023Review
- Assessment of image quality on color fundus retinal images using the automatic retinal image analysis.Scientific reports · 2022Article
- A Review of Intraocular Biomolecules in Retinal Vein Occlusion: Toward Potential Biomarkers for Companion Diagnostics.Frontiers in pharmacology · 2022Review
- Review: The Development of Risk Factors and Cytokines in Retinal Vein Occlusion.Frontiers in medicine · 2022Review
- Prognostic Factor Study of Macular Edema Recurrence in Retinal Vein Occlusion after Conbercept Treatment: A Post Hoc Analysis of the FALCON Study.Computational and mathematical methods in medicine · 2022Article
- Phenotyping of retinal neovascularization in ischemic retinal vein occlusion using wide field OCT angiography.Eye (London, England) · 2021Article
- Long-term outcomes of intravitreal activated protein C injection for ischemic central retinal vein occlusion: an extension trial.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2021Article
- Continuous wavelet transform analysis of ERG in patients with diabetic retinopathy.Documenta ophthalmologica. Advances in ophthalmology · 2021Article
- Baseline clinical features predict visual outcome in young patients with central retinal vein occlusion.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2020Article
- Altered intrinsic functional connectivity of the primary visual cortex in patients with retinal vein occlusion: a resting-state fMRI study.Quantitative imaging in medicine and surgery · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 1 country.
Funding
Abstract
purposeTo investigate in The Standard Care versus COrticosteroid for REtinal Vein Occlusion (SCORE) Study: (1) incidences of neovascular events and retinal capillary nonperfusion (abbreviated as "nonperfusion"), and their relationship with treatment groups; (2) neovascular incidences by nonperfusion status; and (3) pertinent baseline factors for their potential risk for neovascular events.
designTwo multicenter, randomized clinical trials, 1 evaluating participants with central retinal vein occlusion (CRVO) and the other evaluating participants with branch retinal vein occlusion (BRVO).
participantsAt 36 months, data were available for 81 participants with CRVO and 128 with BRVO.
interventionStandard care (observation or grid photocoagulation) versus 1 or 4 mg intravitreal triamcinolone.
main outcome measuresNeovascularization of the iris (NVI), neovascular glaucoma (NVG), disc or retinal neovascularization (NVD/NVE), preretinal or vitreous hemorrhage (PRH/VH), and nonperfusion.
resultsThe cumulative 36-month incidences for CRVO and BRVO eyes, respectively, were 8.5% and 2.4% for NVI or NVG; 8.8% and 7.6% for NVD/NVE or PRH/VH. There were no differences in incidences of neovascular events or risk of nonperfusion when comparing the 3 treatment groups within diseases. For CRVO at 36 months, 16.6% of eyes with ≥5.5 disc areas of nonperfusion versus 4.0% of eyes with <5.5 disc areas of nonperfusion developed NVG (P = 0.0003); for BRVO at 36 months, 14.6% versus 2.4% developed NVD/NVE (P<0.0001). Similar results were noted for most other neovascular events. Nonperfusion was the only significant baseline factor for neovascularization in BRVO, with the risk of a neovascular event increasing with greater disc areas of nonperfusion, and the highest risk noted at ≥5.5 disc areas.
conclusionsIn the SCORE Study, triamcinolone treatment was not associated with lower incidences of neovascular events or nonperfusion status compared with observation or grid photocoagulation. Cumulative 36-month incidences for most neovascular events were significantly higher for nonperfused than perfused eyes. Greater baseline disc areas of nonperfusion increased the risk of neovascularization in BRVO but not CRVO eyes, possibly owing to obscuration of retinal capillary details caused by dense hemorrhage at baseline for CRVO eyes. Increased risk of neovascularization was noted below the historical threshold of 10 disc areas of nonperfusion for retinal vein occlusion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.